Journal article
The role of metformin as a treatment for neuropsychiatric illness
S Dodd, L Sominsky, D Siskind, CC Bortolasci, AF Carvalho, M Maes, AJ Walker, K Walder, AR Yung, LJ Williams, H Myles, T Watson, M Berk
European Neuropsychopharmacology | ELSEVIER | Published : 2022
Abstract
Advances in psychopharmacology have been significantly slower to evolve than in other disciplines of medicine and therefore investigation into novel therapeutic approaches is required. Additionally, concurrent metabolic conditions are prevalent among people with mental disorders. Metformin is a widely used hypoglycaemic agent that is now being studied for use beyond diabetes management. Evidence is emerging that metformin has multiple effects on diverse neurobiological pathways and consequently may be repurposed for treating mental illness. Metformin may have beneficial neuroimmunological, neuroplastic, neuro-oxidative and neuro-nitrosative effects across a range of psychiatric and neurodege..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
MB is supported by a NHMRC Senior Principal Research Fellowship 1059660 and 1156072. DS is supported in part by an NHMRC Emerging Leadership Fellowship 1194635. LW is supported by an NHMRC Emerging Leadership Fellowship (1174060). AJW is supported by a Trisno Family Fellowship and by an NHMRC CRE (1153607)